Author

Ross C. Gruber

Sanofi (United States)ORCID 0000-0002-6745-8767Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Neuroscience· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Assay:imaging· 1 Organism:mouse· 1 Organism:non-human primate· 1

Frequent Co-Authors

Dimitry OfengeimiD· 2 shared Anna WilliamsiD· 1 shared Anza DarehshouriiD· 1 shared Arlo Simmerman· 1 shared Clara MutschleriD· 1 shared Connon I. ThomasiD· 1 shared Crystal R. McClain· 1 shared Dustin P. FykstraiD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersNeuroscience

Dimitry OfengeimORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Microglia drive demyelination via multiple sclerosis antibodies and BTK signaling

Lindsay A. Osso, Helena J. Barr, Michael E. Stockton, Maureen Wentling, Stephanie Karas, Rongchen Huang, Graham C. Peet, Katherine S. Given, Arlo Simmerman, Crystal R. McClain, Mohammad Mansoor, Dustin P. Fykstra, Kellie Horan, Clara Mutschler, Connon I. Thomas, , Ethan G. Hughes

This study shows microglia drive myelin loss in MS through autoantibodies and BTK signaling, with implications for therapeutic targeting.

bioRxiv · Sep 1, 2026 · PreprintNeuroscience

Comparative CNS Pharmacology of the Brutons Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis.

Timothy J. Turner, Pricilla Brun, Ross C. Gruber, Dimitry Ofengeim

This paper compares the CNS pharmacology of three BTK inhibitors in non-human primates, finding that tolebrutinib achieves higher CSF exposure than the others.

Drugs in R&D · Jun 1, 2024Peer-reviewedPharmacology & Toxicology